FDA extends priority review of oral MS drug Cladribine
FDA extends priority review of oral MS drug Cladribine
The U.S. drugs watchdog will take more time to decide over Merck KGaA's multiple sclerosis (MS) pill, the German company said on Friday, two months after drawing a rejection from European regulators.
The U.S. Food and Drug Administration (FDA) extended its review period for cladribine pills as a therapy for relapsing forms of (MS) by three months to Feb. 28, 2011, Merck said.
"The FDA extended the review period to provide additional time for a full review of additional information provided under the new drug application," the company added.... [Read More] - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1840 Views
-
Last post by frodo
-
- 0 Replies
- 1970 Views
-
Last post by NHE
-
- 0 Replies
- 1209 Views
-
Last post by frodo
-
- 1 Replies
- 1683 Views
-
Last post by frodo
-
- 0 Replies
- 1675 Views
-
Last post by frodo
-
- 0 Replies
- 1179 Views
-
Last post by NHE
-
- 0 Replies
- 976 Views
-
Last post by frodo
-
- 0 Replies
- 1058 Views
-
Last post by frodo
-
- 1 Replies
- 1376 Views
-
Last post by NHE